Insider Selling: Paul D. Arata Sells 7,500 Shares of InterMune Stock (ITMN)
InterMune (NASDAQ:ITMN) EVP Paul D. Arata unloaded 7,500 shares of the stock on the open market in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $50.00, for a total value of $375,000.00. Following the transaction, the executive vice president now directly owns 21,913 shares in the company, valued at approximately $1,095,650. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
ITMN has been the subject of a number of recent research reports. Analysts at Goldman Sachs downgraded shares of InterMune from a “buy” rating to a “neutral” rating in a research note on Thursday. They now have a $49.00 price target on the stock, down previously from $52.06. They noted that the move was a valuation call. Separately, analysts at William Blair raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Friday, August 8th. Finally, analysts at Stifel Nicolaus raised their price target on shares of InterMune from $51.00 to $53.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $45.15.
Shares of InterMune (NASDAQ:ITMN) opened at 51.40 on Monday. InterMune has a 52 week low of $10.95 and a 52 week high of $54.57. The stock’s 50-day moving average is $44.50 and its 200-day moving average is $34.74. The company’s market cap is $5.550 billion.
InterMune (NASDAQ:ITMN) last released its earnings data on Wednesday, August 6th. The company reported ($0.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter last year, the company posted ($0.77) earnings per share. InterMune’s revenue was up 141.2% compared to the same quarter last year. On average, analysts predict that InterMune will post $-2.73 earnings per share for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.